weight
Obesity and GLP-1 Medications
Obesity (BMI ≥30) is now recognized as a chronic disease with FDA-approved GLP-1 treatments including semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda). These medications address the biological drivers of weight regain.
15-22%
Average weight loss
70-90%
Patients losing 10%+
60-70%
Maintenance at 2 years
How GLP-1 Medications Help
GLP-1 medications treat obesity by targeting the hormonal and neural pathways that defend against weight loss. When you lose weight, your body naturally increases hunger hormones and decreases satiety signals—a phenomenon called metabolic adaptation that drives weight regain. GLP-1s counteract this by mimicking natural satiety hormones, reducing appetite, increasing fullness, and dampening food cravings. They also slow gastric emptying, keeping food in your stomach longer. Unlike stimulant appetite suppressants, GLP-1s work through physiological mechanisms rather than simply masking hunger. Studies show sustained weight loss of 15-22% at one year, with many patients maintaining significant loss at 2+ years. This level of weight reduction can resolve or improve obesity-related conditions including type 2 diabetes, sleep apnea, and fatty liver disease.
Recommended Medications
Tirzepatide (Zepbound) achieves the highest weight loss at 20.9% average reduction, followed by semaglutide 2.4mg (Wegovy) at 14.9%. Liraglutide (Saxenda) offers 8-10% loss but requires daily injections. For patients with obesity and cardiovascular disease, Wegovy recently received FDA approval for cardiovascular risk reduction based on the SELECT trial. Compounded semaglutide and tirzepatide provide cost-effective alternatives during brand shortages, though quality varies by pharmacy. Retatrutide, a triple agonist in trials, has shown unprecedented 24% weight loss. Your provider will consider your weight loss goals, medical history, insurance coverage, and preference for injection frequency when selecting medication.
What to Expect
Weight loss typically begins within 2-4 weeks of starting GLP-1 therapy, with the most rapid loss occurring in months 3-6. Average weight loss plateaus around month 9-12 at 15-20% of starting weight for semaglutide and tirzepatide. During the first 2-4 weeks, you'll experience dose titration with gradually increasing doses to minimize nausea. Common side effects include nausea (44%), diarrhea (30%), and constipation (24%), which usually improve after 4-8 weeks. Many patients report reduced food noise and cravings, making dietary adherence easier. Weight loss often improves energy, mobility, sleep quality, and self-esteem. Maintenance dosing may be needed long-term to sustain results, as stopping medication typically leads to weight regain within 12 months.
Finding a Provider
Obesity medicine specialists, endocrinologists, and comprehensive weight management programs offer the expertise needed for successful GLP-1 treatment. GLP1Search.com helps you find providers who understand obesity as a chronic disease and offer evidence-based treatments beyond simple diet and exercise advice. Many telehealth platforms now specialize in medical weight loss with GLP-1s, providing convenient access to prescriptions, monitoring, and lifestyle support. Look for providers who offer comprehensive care including nutrition counseling, behavioral support, and management of obesity-related conditions.
Medications commonly used
Find providers who understand obesity
Compare GLP-1 providers by clinical oversight, medication options, pricing, and local availability.
Related conditions